ODI Pharma (ODI) Q3 25/26 earnings summary

Executive summary

• Achieved record sales for the nine months ended March 2026, surpassing any previous full fiscal year.

• Year-to-date sales and profitability reflect strong commercial execution and improved market conditions.

• Market share in Poland continues to grow, supported by key contracts and operational stability.

• Strategy remains focused on disciplined execution, sustainable growth, and expansion in regulated European medical cannabis markets.

Financial highlights

• Q3 2026 net sales: SEK 12,712,029, up 348% year-over-year (Q3 2025: SEK 2,934,337).

• Nine-month net sales: SEK 29,753,825, up from SEK 3,064,896 year-over-year.

• Q3 profit after financial items: SEK 126,614 (Q3 2025: -340,612); nine-month profit: SEK 1,417,177 (prior year: -4,153,493).

• Q3 operating income: SEK 309,935 (Q3 2025: -215,319); nine-month operating income: SEK 1,937,931 (prior year: -3,653,746).

• Earnings per share for nine months: SEK 0.08 (prior year: -0.26).

Outlook and guidance

• Continued focus on both strategic and organic expansion in European medical cannabis markets.

• Operational stability and strengthened balance sheet position the company for further growth.

• No change in strategy; emphasis on disciplined execution and long-term value creation.